Supported by the Bill and Melinda Gates Foundation (research grants OPP47674 and OOP52516) and the National Institutes of Health (research grants R01 MH095507 and P30 AI 027757).
JAIDS Journal of Acquired Immune Deficiency Syndromes
Highly active Antiretroviral Therapy--methods, HIV infections Patients, Antiretrovirals
Sharing of pre-exposure prophylaxis (PrEP) medications is a concern for PrEP implementation. For HIV-1 serodiscordant couples, sharing may undermine the HIV-1 prevention benefit and also cause antiretroviral resistance if taken by HIV-1 infected partners. Within a PrEP efficacy trial among HIV-1 serodiscordant couples, we assessed the occurrence of PrEP sharing by self-report and plasma tenofovir concentrations in HIV-1 infected partners. PrEP sharing was self-reported at < 0.01% of visits, and 0% -1.6% of randomly selected and 0% of purposively selected specimens from HIV-1 infected participants had detectable tenofovir concentrations (median: 66.5 ng/mL, range: 1.3-292 ng/mL). PrEP sharing within HIV-1 serodiscordant couples was extremely rare.
Locate the Document
Thomson, K. A., Haberer, J. E., Marzinke, M. A., Mujugira, A., Hendrix, C. W., Celum, C., & ... Baeten, J. M. (2017). Brief Report: Medication Sharing Is Rare Among African HIV-1 Serodiscordant Couples Enrolled in an Efficacy Trial of Oral Pre-exposure Prophylaxis (PrEP) for HIV-1 Prevention. Journal Of Acquired Immune Deficiency Syndromes (1999), 75(2), 184-189.